组成性雄烷受体遗传多态性与个体化治疗

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (12): 1432-1440.

• 综述与讲座 • 上一篇

组成性雄烷受体遗传多态性与个体化治疗

魏婉慧¹，李玲^1,2，何名扬¹，赵慧佳¹，徐千¹，时玉颖¹，乐江²，王彦峰¹，叶啟发^1,3

¹武汉大学中南医院，武汉大学肝胆疾病研究院，武汉大学移植医学中心，移植医学技术湖北省重点实验室，武汉 430071，湖北； ²武汉大学基础医学院药理教研室，武汉 430071，湖北； ³中南大学湘雅三医院，卫生部移植医学工程技术研究中心，长沙 410013，湖南

收稿日期:2017-05-09 修回日期:2017-06-12 出版日期:2017-12-26 发布日期:2018-01-02
通讯作者: 叶啟发，男，教授，主任医师，研究方向：肝胆外科，器官移植。 Tel: 027-67812988 E-mail: yqf_china@163.com
作者简介:魏婉慧，女，本科，研究方向：基因多态性与药物代谢的相关性。 Tel:15271821476 E-mail:1328815774@qq.com
基金资助:
湖北省自然科学基金创新群体（2015CFA018）；湖北省卫计委药护技和管理专项（WJ2017H0024）；武汉大学中南医院药护技和管理专项（xcpy20160062）

Relevance of CAR genetic polymorphism and individual therapy

WEI Wanhui ¹ , LI Ling ^1,2, HE Mingyang¹, ZHAO Huijia ¹, XU Qian ¹, SHI Yuying ¹, YUE Jiang ², WANG Yanfeng ¹, YE Qifa ^1,3

¹Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan 430071, Hubei, China;² Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071, Hubei, China; ³ the 3rd Xiangya Hospital of Central South University, Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Changsha 410013, Hunan, China

Received:2017-05-09 Revised:2017-06-12 Online:2017-12-26 Published:2018-01-02

摘要/Abstract

摘要：

组成性雄烷受体（constitutive androstane receptor, CAR）通过调控细胞色素P450（cytochromeP450, CYP450）等一相代谢酶、UDP-葡萄糖醛酸转移酶（UDP-glucuronosyltransferases, UGTs）等二相代谢酶及多药耐药相关蛋白（multidrug resistance-associated protein, MRP）等药物转运体等代谢相关基因，对外源性药物代谢及维系体内血糖、血脂、胆红素等多种内源性物质的代谢平衡发挥重要作用。作为体内物质代谢的枢纽，CAR直接影响了代谢性疾病的发生以及多种药物的疗效，对其多态性的研究有利于从基因层面解释个体化治疗的差异性，预见相关疾病的发生进展。本文拟就近几年来CAR单核苷酸多态性影响物质代谢的相关研究作一综述，探究CAR多态性与物质代谢的相关性，为临床上疾病的发生及药物用法用量的提前预测提供科学依据。

关键词: 组成性雄烷受体（CAR）, 多态性, 物质代谢

Abstract:

Regulating phase I and II enzyme, drug transporters and constitutive androstane receptor (CAR) play an important role in dug metabolism and keeping balance on the levels of glucose, lipids and hormone in serum. As a hub of material metabolism within body, CAR can affect the efficacy of various drugs and be involved in many common metabolic diseases. Studying its polymorphism is referential for explaining the individual difference genetically and predicting the occurrence and development of diseases. This review focuses on the correlation between the CAR polymorphism and metabolic, which provides evidence for predicting the development of disease and choosing clinical drug dosage.

Key words: constitutive androstane receptor (CAR), polymorphism, material metabolism

中图分类号:

R968

魏婉慧，李玲，何名扬，赵慧佳，徐千，时玉颖，乐江，王彦峰，叶啟发. 组成性雄烷受体遗传多态性与个体化治疗[J]. 中国临床药理学与治疗学, 2017, 22(12): 1432-1440.

WEI Wanhui, LI Ling, HE Mingyang, ZHAO Huijia, XU Qian, SHI Yuying, YUE Jiang, WANG Yanfeng, YE Qifa. Relevance of CAR genetic polymorphism and individual therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1432-1440.

参考文献

［1］Baes M, Gulick T, Choi HS, et al. A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements［J］. Mol Cell Biol, 1994, 14(3): 1544-1552.
［2］Choi HS, Chung M, Tzameli I, et al. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR［J］. J Biol Chem, 1997, 272(38): 23565-23571.
［3］Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta［J］. Nature, 1998, 395(6702): 612-615.
［4］Mackowiak B, Wang H. Mechanisms of xenobiotic receptor activation: Direct vs indirect ［J］. Biochim Biophys Acta, 2016, 1859(9): 1130-1140.
［5］Swart M, Whitehorn H, Ren Y, et al. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients ［J］. BMC Med Genet, 2012, 13: 112.
［6］Kobayashi K, Hashimoto M, Honkakoski P, et al. Regulation of gene expression by CAR: an update［J］. Arch Toxicol, 2015, 89(7): 1045-1055.
［7］Chai SC, Cherian MT, Wang YM, et al. Small-molecule modulators of PXR and CAR［J］. Biochim Biophys Acta, 2016, 1859(9): 1141-1154.
［8］Aleksunes LM, Klaassen CD. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARalpha-, and Nrf2-null mice［J］. Drug Metab Dispos, 2012, 40(7): 1366-1379.
［9］van der Mark VA, Rudi DWD, Shevchenko V, et al. Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells［J］. Drug Metab Dispos, 2017, 45(1): 56-67.
［10］Hedrich WD, Xiao J, Heyward S, et al. Activation of the constitutive androstane receptor increases the therapeutic index of CHOP in lymphoma treatment ［J］. Mol Cancer Ther, 2016, 15(3): 392-401.
［11］Cheung TP, Van Rostenberghe H, Ismail R, et al. High resolution melting analysis of the NR1I3 genetic variants: Is there an association with neonatal hyperbilirubinemia? ［J］. Gene, 2015, 573(2): 198-204.
［12］Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions［J］. Acta Pharm Sin B, 2016, 6(5): 413-425.
［13］Hori T, Moore R, Negishi M. p38 MAP kinase links CAR activation and inactivation in the nucleus via phosphorylation at threonine 38［J］. Drug Metab Dispos, 2016, 44(6): 871-876.
［14］Yasujima T, Saito K, Moore R, et al. Phenobarbital and insulin reciprocate activation of the nuclear receptor constitutive androstane receptor through the insulin receptor［J］. J Pharmacol Exp Ther, 2016, 357(2): 367-374.
［15］Wang X, Zheng L, Wu J, et al. Constitutive androstane receptor activation promotes bilirubin clearance in a murine model of alcoholic liver disease［J］. Mol Med Rep, 2017, 15(6): 3459-3466.
［16］Matsui K, Maruo Y, Sato H, et al. Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome［J］. BMC Gastroenterol, 2010, 10: 57.
［17］Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease ［J］. Metabolism, 2016, 65(8): 1026-1037.
［18］Marmugi A, Lukowicz C, Lasserre F, et al. Activation of the constitutive androstane receptor induces hepatic lipogenesis and regulates Pnpla3 gene expression in a LXR-independent way［J］. Toxicol Appl Pharmacol, 2016, 303: 90-100.
［19］Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy ［J］. Pharmacol Rev, 2014, 66(4): 948-983.
［20］Cheng S, Zou M, Liu Q, et al. Activation of constitutive androstane receptor prevents cholesterol gallstone formation ［J］. Am J Pathol, 2017, 187(4): 808-818.
［21］Schraplau A, Schewe B, Neuschafer-Rube F, et al. Enhanced thyroid hormone breakdown in hepatocytes by mutual induction of the constitutive androstane receptor (CAR, NR1I3) and arylhydrocarbon receptor by benzo［a］pyrene and phenobarbital［J］. Toxicology, 2015, 328: 21-28.
［22］Bing Y, Zhu S, Jiang K, et al. Reduction of thyroid hormones triggers down-regulation of hepatic CYP2B through nuclear receptors CAR and TR in a rat model of acute stroke［J］. Biochem Pharmacol, 2014, 87(4): 636-649.
［23］Supek F. The code of silence: widespread associations between synonymous codon biases and gene function［J］. J Mol Evol, 2016, 82(1): 65-73.
［24］van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity［J］. J Clin Oncol, 2009, 27(26): 4406-4412.
［25］van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib［J］. Clin Cancer Res, 2011, 17(3): 620-629.
［26］Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients ［J］. Pharmacogenomics J, 2008, 8(2): 139-146.
［27］Chew SC, Lim J, Singh O, et al. Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRalpha and HNF4alpha) on docetaxel disposition in Chinese nasopharyngeal cancer patients ［J］. Eur J Clin Pharmacol, 2014, 70(2): 155-166.
［28］Wyen C, Hendra H, Siccardi M, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens ［J］. J Antimicrob Chemother, 2011, 66(9): 2092-2098.
［29］Olagunju A, Siccardi M, Amara A, et al. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients［J］. Ther Drug Monit, 2014, 36(6): 734-738.
［30］Zang M, Zhao L, Zhu F, et al. Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects ［J］. Drug Metab Pharmacokinet, 2015, 30(1): 123-126.
［31］Narjoz C, Cessot A, Thomas-Schoemann A, et al. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients［J］. Invest New Drugs, 2015, 33(1): 257-268.
［32］Tham LS, Holford NH, Hor SY, et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics ［J］. Clin Cancer Res, 2007, 13(23): 7126-7132.
［33］Cusato J, Tomasello C, Simiele M, et al. Efavirenz pharmacogenetics in a cohort of Italian patients［J］. Int J Antimicrob Agents, 2016, 47(2): 117-123.
［34］Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication ［J］. Antivir Ther, 2008, 13(5): 675-685.
［35］Lima LO, Bruxel EM, Hutz MH, et al. Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy［J］. Arq Bras Endocrinol Metabol, 2013, 57(7): 513-519.
［36］Moon JY, Chang BC, Lee KE, et al. Effects of pregnane x receptor genetic polymorphisms on stable warfarin doses ［J］. J Cardiovasc Pharmacol Ther, 2015, 20(6): 532-538.
［37］Dickinson L, Amin J, Else L, et al. Pharmacokinetic and pharmacodynamic comparison of once-daily efavirenz (400 mg vs 600 mg) in treatment-naive hiv-infected patients: results of the encore1 study ［J］. Clin Pharmacol Ther, 2015, 98(4): 406-416.
［38］Olagunju A, Bolaji O, Amara A, et al. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study ［J］. Clin Infect Dis, 2015, 61(3): 453-463.
［39］Chen D, Guo F, Shi J, et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients ［J］. Drug Metab Pharmacokinet, 2014, 29(3): 249-253.
［40］Kaupert LC, Lemos-Marini SH, De Mello MP, et al. The effect of fetal androgen metabolism-related gene variants on external genitalia virilization in congenital adrenal hyperplasia ［J］. Clin Genet, 2013, 84(5): 482-488.
［41］Lima LO, Almeida S, Hutz MH, et al. PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms and lipid and lipoprotein levels in a Southern Brazilian population ［J］. Mol Biol Rep, 2013, 40(2): 1241-1247.
［42］Urano T, Usui T, Shiraki M, et al. Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density ［J］. Geriatr Gerontol Int, 2009, 9(3): 235-241.
［43］许新，纪莉莎，芦琳琳，等. 药物性肝损伤发病机制的研究进展［J］. 临床肝胆病杂志, 2016, 32(2): 382-385.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[4]	周晶, 周琛, 廖珂, 邱爱林, 董巍檑, 郭紫芬. 孕激素受体基因G1978T 多态性与子宫内膜癌的相关性研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 400-406.
[5]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[6]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[7]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[8]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[9]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[10]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[11]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[12]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.
[13]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[14]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[15]	杨春艳, 张文, 王培培, 彭静, 江佳, 宋静, 刘俊, 李越然, 杨魁, 汪盛, 徐振宇, 栾家杰. 叶酸代谢通路相关基因多态性对血清同型半胱氨酸浓度的影响[J]. 中国临床药理学与治疗学, 2021, 26(11): 1259-1264.

组成性雄烷受体遗传多态性与个体化治疗

Relevance of CAR genetic polymorphism and individual therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价